Determination of disk diffusion and MIC quality control guidelines for JNJ-Q2, a novel quinolone

JNJ-Q2 is a novel fluorinated 4-quinolone in development for treatment of acute bacterial skin and skin structure infection and community-acquired bacterial pneumonia. This quality control (QC) study was performed to establish ranges for control strains: Staphylococcus aureus ATCC 29213 (0.004 to 0.015 μg/ml), Enterococcus faecalis ATCC 29212 (0.015 to 0.06 μg/ml), Pseudomonas aeruginosa ATCC 27853 (0.5 to 2 μg/ml and 17 to 23 mm), Escherichia coli ATCC 25922 (0.008 to 0.03 μg/ml and 30 to 36 mm), Haemophilus influenzae ATCC 49247 (0.002 to 0.015 μg/ml and 31 to 39 mm), Streptococcus pneumoniae ATCC 49619 (0.004 to 0.015 μg/ml and 28 to 35 mm), and S. aureus ATCC 25923 (32 to 38 mm). These ranges will be crucial in evaluating JNJ-Q2 potency as it progresses through clinical trial development.